研究者業績

澁谷 和幹

Kazumoto Shibuya

基本情報

所属
千葉大学 医学部附属病院
学位
医学博士(2012年3月)

J-GLOBAL ID
201801007335779285
researchmap会員ID
B000347049

論文

 197
  • Atsuhiko Sugiyama, Yosuke Onishi, Kimiko Ito, Kazumoto Shibuya, Keigo Nakamura, Fumiko Oda, Ichizo Nishino, Shigeaki Suzuki, Satoshi Kuwabara
    Internal medicine (Tokyo, Japan) 60(16) 2671-2675 2021年3月1日  
    We herein report a case of seronegative immune-mediated necrotizing myopathy (IMNM) concurrent with anti-Kv1.4 and anti-titin antibodies. A 72-year-old Japanese woman presented with a 29-year history of fluctuating high serum creatine kinase (CK) levels followed by intermittent ptosis and respiratory muscle weakness. This case highlights the fact that marked respiratory muscle weakness requiring intubation can be seen in an ambulant patient with IMNM. Marked respiratory muscle weakness, rhabdomyolysis-like acute elevation of CK levels, and anti-striational muscle antibodies may be a characteristic constellation of findings in a distinct subgroup of patients with inflammatory myopathy with myasthenia gravis or similar symptoms.
  • Kazumoto Shibuya, Setsu Sawai, Atsuhiko Sugiyama, Mizuho Koide, Ayumi Nishiyama, Masashi Aoki, Satoshi Kuwabara
    Amyotrophic lateral sclerosis & frontotemporal degeneration 22(1-2) 144-146 2021年2月  
    We describe a 48-year-old man, suffering from difficulties in closing his eyes. He subsequently experienced progressive weakness in the facial and bulbar regions and upper limbs. His father and paternal grandmother had limb weakness as initial manifestations and were diagnosed with amyotrophic lateral sclerosis (ALS). In the present case, neuroimaging and laboratory studies were unremarkable, and neurophysiological studies disclosed diffuse denervation. Genetic testing identified a heterozygous c.10A>G, p.K4E (K3E) variant in superoxide dismutase 1 (SOD1) gene, and he was diagnosed with familial ALS. In ALS, facial muscles are rarely involved as an initial symptom. The present patient is a first case of facial onset ALS with K3E variant in SOD1 gene. Two case reports identified facial palsy as an initial manifestation in familial ALS with C6G variant in SOD1 gene. Several ALS patients with variants in SOD1 gene may have facial onset history.
  • Shoko Yoshii, Kazumoto Shibuya, Hajime Yokota, Hajime Ikehara, Tadashi Shiohama, Daisuke Sawada, Satoshi Kuwabara, Katsunori Fujii
    Brain & development 43(2) 352-356 2021年2月  
    BACKGROUND: Peripheral nerve imaging is increasingly recognized as a powerful tool to evaluate nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Charcot-Marie-Tooth diseases (CMT), whereas data in pediatric patients are limited. CASE DESCRIPTION: We describe the case of a 15-year-old Japanese girl with asymmetric demyelinating polyneuropathy, who, at the age of 10 years, was initially diagnosed with a demyelinating form of CMT. Fluorescence in situ hybridization for peripheral myelin 22 was negative, and already-known pathogenic variants were not detected by whole-genome sequencing, and nerve conduction studies revealed multifocal conduction blocks. Over the next 5 years, the patient showed gradual improvement in muscle weakness and sensory disturbance without immunological treatment and was referred to our hospital. RESULTS: At the age of 15 years, magnetic resonance (MR) neurography showed asymmetric multifocal fusiform enlargement of nerve roots, brachial and lumbosacral plexuses, and intermediated nerve trunks, as well as cranial nerves. Based on the MR neurography findings and multifocal nerve conduction blocks, she was diagnosed as having multifocal CIDP (multifocal demyelinating sensory and motor neuropathy [MADSAM]) according to the European Federation of Neurological Societies/Peripheral Nerve Society diagnostic criteria. DISCUSSION: Clinical diagnosis of childhood CIDP is challenging because its neurological manifestations and nerve conduction study findings occasionally resemble those of inherited demyelinating neuropathies. MR neurography is helpful for the assessment of patterns of nerve hypertrophy; MADSAM-CIDP is characterized by multiple fusiform nerve enlargement, whereas CMT shows symmetric and diffuse nerve hypertrophy. CONCLUSION: The MR neurography patterns would help in diagnosing pediatric demyelinating neuropathies.
  • Smriti Agarwal, Elizabeth Highton-Williamson, Jashelle Caga, James Howells, Thanuja Dharmadasa, José M Matamala, Yan Ma, Kazumoto Shibuya, John R Hodges, Rebekah M Ahmed, Steve Vucic, Matthew C Kiernan
    Scientific reports 11(1) 2172-2172 2021年1月26日  
    Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are well-recognised as an extended disease spectrum. This study hypothesised that cortical hyperexcitability, an early pathophysiological abnormality in ALS, would distinguish cognitive phenotypes, as a surrogate marker of pathological disease burden. 61 patients with ALS, matched for disease duration (pure motor ALS, n = 39; ALS with coexistent FTD, ALS-FTD, n = 12; ALS with cognitive/behavioural abnormalities not meeting FTD criteria, ALS-Cog, n = 10) and 30 age-matched healthy controls. Cognitive function on the Addenbrooke's cognitive examination (ACE) scale, behavioural function on the motor neuron disease behavior scale (MiND-B) and cortical excitability using transcranial magnetic stimulation (TMS) were documented. Cortical resting motor threshold (RMT), lower threshold indicating hyperexcitability, was lower in ALS-FTD (50.2 ± 6.9) compared to controls (64.3 ± 12.6, p < 0.005), while ALS-Cog (63.3 ± 12.7) and ALS (60.8 ± 13.9, not significant) were similar to controls. Short interval intracortical inhibition (SICI) was reduced across all ALS groups compared to controls, indicating hyperexcitability. On receiver operating characteristic curve analysis, RMT differentiated ALS-FTD from ALS (area under the curve AUC = 0.745, p = 0.011). The present study has identified a distinct pattern of cortical excitability across cognitive phenotypes in ALS. As such, assessment of cortical physiology may provide more precise clinical prognostication in ALS.
  • 小島 雄太, 磯瀬 沙希里, 大森 茂樹, 水地 智基, 狩野 裕樹, 中村 圭吾, 鈴木 陽一, 常山 篤子, 澁谷 和幹, 三澤 園子, 桑原 聡
    末梢神経 31(2) 393-393 2020年12月  
  • K. Shibuya, A. Tsuneyama, S. Misawa, T. Suichi, Y. Suzuki, Y. Kojima, K. Nakamura, H. Kano, M. Prado, S. Kuwabara
    European Journal of Neurology 27(12) 2658-2661 2020年12月  
  • 叶内 匡, 夏井 洋和, 飯田 真太朗, 赤座 実穂, 澁谷 和幹, 能登 祐一, 木村 英紀, 清水 俊夫, 水野 敏樹, 桑原 聡, 横田 隆徳
    臨床神経学 60(Suppl.) S409-S409 2020年11月  
  • 林 直毅, 熱田 直樹, 横井 大知, 中村 亮一, 勝野 雅央, 和泉 唯信, 金井 数明, 服部 信孝, 谷口 彰, 森田 光哉, 狩野 修, 澁谷 和幹, 桑原 聡, 鈴木 直輝, 青木 正志, 織田 雅也, 饗場 郁子, 梶 龍兒, 祖父江 元
    臨床神経学 60(Suppl.) S381-S381 2020年11月  
  • 中村 亮一, 熱田 直樹, 藤内 玄規, 林 直毅, 勝野 雅央, 和泉 唯信, 金井 数明, 服部 信孝, 谷口 彰, 森田 光哉, 狩野 修, 澁谷 和幹, 桑原 聡, 鈴木 直輝, 青木 正志, 阿部 康二, 石原 智彦, 小野寺 理, 梶 龍兒, 祖父江 元
    臨床神経学 60(Suppl.) S381-S381 2020年11月  
  • Kazumoto Shibuya, Sonoko Misawa, Akiyuki Uzawa, Setsu Sawai, Atsuko Tsuneyama, Yo-Ichi Suzuki, Tomoki Suichi, Yuta Kojima, Keigo Nakamura, Hiroki Kano, Mario Prado, Satoshi Kuwabara
    Journal of neurology, neurosurgery, and psychiatry 91(11) 1189-1194 2020年11月  
    OBJECTIVE: The 'split hand' sign refers to preferential wasting of the thenar and first dorsal interosseous muscles with relatively sparing of the hypothenar muscles in amyotrophic lateral sclerosis (ALS) and both cortical and spinal/peripheral excitotoxic mechanisms have been proposed. We aimed to study split hand and axonal excitability in spinal and bulbar muscular atrophy (SBMA) in which cortical motor neurons are intact. METHODS: In 35 patients with genetically confirmed SBMA, 55 with ALS, 158 with other neuromuscular diseases and 90 normal controls; split hand was strictly determined by amplitudes of compound muscle action potentials. Nerve excitability testing of median motor axons was performed in 35 SBMA and 55 patients with ALS and 45 normal controls. RESULTS: Split hand was as frequently found for patients with SBMA (57%) and ALS (62%), compared with disease (20%) and normal (0%) controls. Excitability testing showed that in both SBMA and ALS, strength-duration time constant was longer, and threshold changes in depolarising threshold electrotonus and superexcitability in the recovery cycle were greater than in normal controls (p<0.01). CONCLUSIONS: Split hand is not specific to ALS and can be caused by the peripheral mechanism alone in SBMA, whereas the effect of upper motor neuron lesion cannot be excluded in ALS. Our results also suggest that SBMA and ALS share common axonal excitability changes; increased nodal persistent sodium and reduced potassium currents that may accelerate motor neuronal death and differently affect axons-innervating different muscles. Ion channel modulators could be a therapeutic option for both SBMA and ALS.
  • 澁谷 和幹, 常山 篤子, 三澤 園子, 水地 智基, 鈴木 陽一, 小島 雄太, 中村 圭吾, 狩野 裕樹, Prado Mario, 桑原 聡
    神経治療学 37(6) S222-S222 2020年10月  
  • 狩野 裕樹, 澁谷 和幹, 水地 智基, 常山 篤子, 鈴木 陽一, 中村 圭吾, 小島 雄太, 青墳 佑弥, 諸岡 茉里恵, 大谷 亮, 桑原 聡, 三澤 園子
    臨床神経生理学 48(5) 568-568 2020年10月  
  • 鈴木 陽一, 澁谷 和幹, 三澤 園子, 水地 智基, 常山 篤子, 中村 圭吾, 小島 雄太, 狩野 裕樹, 青墳 佑弥, 諸岡 茉里恵, 大谷 亮, MARIO PRADO, 桑原 聡
    臨床神経生理学 48(5) 586-586 2020年10月  
  • 澁谷 和幹, 鈴木 陽一, 三澤 園子, 水地 智基, 常山 篤子, 小島 雄太, 中村 圭吾, 狩野 裕樹, 大谷 亮, 青墳 佑弥, 諸岡 茉里恵, マリオ・プラド, 桑原 聡
    臨床神経生理学 48(5) 586-586 2020年10月  
  • Ryoichi Nakamura, Kazuharu Misawa, Genki Tohnai, Masahiro Nakatochi, Sho Furuhashi, Naoki Atsuta, Naoki Hayashi, Daichi Yokoi, Hazuki Watanabe, Hirohisa Watanabe, Masahisa Katsuno, Yuishin Izumi, Kazuaki Kanai, Nobutaka Hattori, Mitsuya Morita, Akira Taniguchi, Osamu Kano, Masaya Oda, Kazumoto Shibuya, Satoshi Kuwabara, Naoki Suzuki, Masashi Aoki, Yasuyuki Ohta, Toru Yamashita, Koji Abe, Rina Hashimoto, Ikuko Aiba, Koichi Okamoto, Kouichi Mizoguchi, Kazuko Hasegawa, Yohei Okada, Tomohiko Ishihara, Osamu Onodera, Kenji Nakashima, Ryuji Kaji, Yoichiro Kamatani, Shiro Ikegawa, Yukihide Momozawa, Michiaki Kubo, Noriko Ishida, Naoko Minegishi, Masao Nagasaki, Gen Sobue
    Communications biology 3(1) 526-526 2020年9月23日  
    Amyotrophic lateral sclerosis (ALS) is a devastating progressive motor neuron disease that affects people of all ethnicities. Approximately 90% of ALS cases are sporadic and thought to have multifactorial pathogenesis. To understand the genetics of sporadic ALS, we conducted a genome-wide association study using 1,173 sporadic ALS cases and 8,925 controls in a Japanese population. A combined meta-analysis of our Japanese cohort with individuals of European ancestry revealed a significant association at the ACSL5 locus (top SNP p = 2.97 × 10-8). We validated the association with ACSL5 in a replication study with a Chinese population and an independent Japanese population (1941 ALS cases, 3821 controls; top SNP p = 1.82 × 10-4). In the combined meta-analysis, the intronic ACSL5 SNP rs3736947 showed the strongest association (p = 7.81 × 10-11). Using a gene-based analysis of the full multi-ethnic dataset, we uncovered additional genes significantly associated with ALS: ERGIC1, RAPGEF5, FNBP1, and ATXN3. These results advance our understanding of the genetic basis of sporadic ALS.
  • Ho To, Kaho Teshima, Michiha Kon, Saori Yasuda, Yuta Akaike, Kazumoto Shibuya, Shinya Nagai, Chihiro Sasakawa
    Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 32(4) 581-584 2020年7月  
    Two Actinobacillus pleuropneumoniae isolates from clinical cases of porcine pleuropneumonia in Japan were positive in the capsular serovar 15-specific PCR assay, but nontypeable (NT) in the agar gel precipitation (AGP) test. Nucleotide sequence analysis of gene clusters involved in the biosynthesis of capsular polysaccharide (CPS) and lipopolysaccharide O-polysaccharide (O-PS) revealed that both clusters contained transposable element ISApl1 of A. pleuropneumoniae belonging to the IS30 family. Immunoblot analysis revealed that these 2 isolates could not produce O-PS. We conclude that the ISApl1 of A. pleuropneumoniae can interfere in the biosynthesis of both CPS and O-PS.
  • Michio Inoue, Jantima Tanboon, Shinya Hirakawa, Hirofumi Komaki, Takeshi Fukushima, Hiroyuki Awano, Takashi Tajima, Kenji Yamazaki, Ryutaro Hayashi, Tatsuo Mori, Kazumoto Shibuya, Takahiko Yamanoi, Hajime Yoshimura, Tomohiro Ogawa, Atsushi Katayama, Fuminobu Sugai, Yoichi Nakayama, Satoko Yamaguchi, Shinichiro Hayashi, Satoru Noguchi, Hisateru Tachimori, Naoko Okiyama, Manabu Fujimoto, Ichizo Nishino
    JAMA neurology 77(7) 872-877 2020年7月1日  
    Importance: Reports on dermatomyositis (DM) sine dermatitis (DMSD) are scarce, and the concept of the disease has not been widely accepted. Objective: To confirm the existence of DMSD, determine its prevalence, and characterize its serologic features. Design, Setting, and Participants: This is a cohort study that reviewed clinical information, laboratory data, and muscle pathology slides from January 2009 to August 2019. We further assessed the follow-up data of 14 patients with DMSD. The median (interquartile range) follow-up period was 34 (16-64) months. Muscle biopsy samples, along with clinical information and laboratory data, were sent to a referral center for muscle diseases in Japan for diagnosis. Of patients whose myopathologic diagnosis was made at the National Center of Neurology and Psychiatry between January 2009 and August 2019, 199 patients were eligible for inclusion. These patients underwent full investigation for DM-specific autoantibodies (against transcriptional intermediary factor γ, Mi-2, melanoma differentiation-associated gene 5, nuclear matrix protein 2 [NXP-2], and small ubiquitin-like modifier activating enzyme ); however, 17 patients were excluded because their muscle fibers did not express myxovirus resistance protein A, a sensitive and specific marker of DM muscle pathology. Main Outcomes and Measures: Diagnosis of DMSD was based on the absence of a skin rash at the time of muscle biopsy. Results: Of the 182 patients, 93 were women (51%) and 46 were children (25%) (<18 years). Fourteen patients (8%) had DMSD and none were clinically diagnosed with DM. Among the 14 patients with DMSD, 12 (86%) were positive for anti-NXP-2 autoantibodies, while the remaining 2 were positive for anti-transcriptional intermediary factor γ and anti-Mi-2 autoantibodies, respectively. Only 28% of patients (47 of 168) with a skin rash were positive for anti-NXP-2 autoantibodies, indicating a significant association between anti-NXP-2 autoantibodies and DMSD (86% [12 of 14] vs 28% [47 of 168]; P < .001). This association was also supported by multivariable models adjusted for disease duration (odds ratio, 126.47; 95% CI, 11.42-1400.64; P < .001). Conclusions and Relevance: Dermatomyositis sine dermatitis does exist and accounts for 8% of patients with DM confirmed with muscle biopsy. Dermatomyositis sine dermatitis is significantly associated with anti-NXP-2 autoantibodies, which contrasts with anti-MDA5 DM, which is typically clinically amyopathic in presentation. It is essential to distinguish DMSD from other types of myositis because DM-specific therapies that are currently under development, including Janus kinase inhibitors, may be effective for DMSD.
  • Tomoki Suichi, Sonoko Misawa, Yukari Sekiguchi, Kazumoto Shibuya, Atsuko Tsuneyama, Yo-Ichi Suzuki, Keigo Nakamura, Hiroki Kano, Satoshi Kuwabara
    Journal of the neurological sciences 413 116771-116771 2020年6月15日  査読有り
    POEMS (polyneuropathy, organomegaly, endocrinopathy monoclonal gammopathy, and skin changes) syndrome is occasionally associated with Castleman disease (CD) and their prognosis is considered as poorer than that in POEMS alone patients. To elucidate recent prognosis of POEMS syndrome coexisting with CD, we reviewed clinical data of 102 patients with POEMS syndrome treated at our institution between 2000 and 2018 and compared clinical characteristics, response to treatment, and prognosis between POEMS patients with biopsy-proven CD (POEMS-CD) and those without it. Fourteen POEMS-CD patients and 56 POEMS alone patients were identified, and the remaining 32 patients with unbiopsied lymphadenopathy were excluded. POEMS-CD patients significantly showed earlier onset and less severe neuropathic symptoms. Most of the POEMS-CD patients were treated with thalidomide and dexamethasone (n = 10, 71%), and subsequently received autologous stem cell transplantation (n = 6, 43%). Response to thalidomide was better in patients with POEMS-CD than those with POEMS alone (90% vs 43% clinical response, [p = .012]; 80% vs 45% normalization of serum VEGF levels, [p = .079]). The 10-year overall survival (95% confidence interval) was 89% (50-98%) in POEMS-CD patients and 61% (42-77%) in those with POEMS alone. POEMS syndrome associated with CD constitutes a subgroup of POEMS syndromes characterized by earlier onset, mild polyneuropathy, and favorable response to treatment. Recognition of this subgroup is significant for determination of therapeutic strategy.
  • Kohei Hamanaka, Darina Šikrová, Satomi Mitsuhashi, Hiroki Masuda, Yukari Sekiguchi, Atsuhiko Sugiyama, Kazumoto Shibuya, Richard J L F Lemmers, Remko Goossens, Megumu Ogawa, Koji Nagao, Chikashi Obuse, Satoru Noguchi, Yukiko K Hayashi, Satoshi Kuwabara, Judit Balog, Ichizo Nishino, Silvère M van der Maarel
    Neurology 94(23) e2441-e2447 2020年6月9日  
    OBJECTIVE: Facioscapulohumeral muscular dystrophy (FSHD) is a heterogenetic disorder predominantly characterized by progressive facial and scapular muscle weakness. Patients with FSHD either have a contraction of the D4Z4 repeat on chromosome 4q35 or mutations in D4Z4 chromatin modifiers SMCHD1 and DNMT3B, both causing D4Z4 chromatin relaxation and inappropriate expression of the D4Z4-encoded DUX4 gene in skeletal muscle. In this study, we tested the hypothesis whether LRIF1, a known SMCHD1 protein interactor, is a disease gene for idiopathic FSHD2. METHODS: Clinical examination of a patient with idiopathic FSHD2 was combined with pathologic muscle biopsy examination and with genetic, epigenetic, and molecular studies. RESULTS: A homozygous LRIF1 mutation was identified in a patient with a clinical phenotype consistent with FSHD. This mutation resulted in the absence of the long isoform of LRIF1 protein, D4Z4 chromatin relaxation, and DUX4 and DUX4 target gene expression in myonuclei, all molecular and epigenetic hallmarks of FSHD. In concordance, LRIF1 was shown to bind to the D4Z4 repeat, and knockdown of the LRIF1 long isoform in muscle cells results in DUX4 and DUX4 target gene expression. CONCLUSION: LRIF1 is a bona fide disease gene for FSHD2. This study further reinforces the unifying genetic mechanism, which postulates that FSHD is caused by D4Z4 chromatin relaxation, resulting in inappropriate DUX4 expression in skeletal muscle.
  • Yuta Kojima, Akiyuki Uzawa, Kazumoto Shibuya, Manato Yasuda, Yukiko Ozawa, Fumiko Oda, Hirokazu Shiraishi, Masakatsu Motomura, Satoshi Kuwabara
    Clinical and Experimental Neuroimmunology 11(2) 131-134 2020年5月1日  
    Objective: Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic neurological syndrome, most frequently associated with small-cell lung carcinoma (SCLC). The survival of LEMS patients depends on the presence of SCLC, whereas the functional outcome in patients without SCLC has not been fully clarified. The aim of this study was to elucidate the long-term prognosis of LEMS patients with or without SCLC. Methods: We collected data from seven consecutive Japanese patients with LEMS without SCLC (n = 4) or LEMS with SCLC (n = 3) consulting Chiba university hospital, Chiba, Japan from 2003 to 2019. The functional disability was assessed with the modified Rankin Scale. Results: The median observation period was 52 months (range 18–168 months); one LEMS with SCLC patient died as a result of SCLC 18 months after diagnosis, whereas the remaining two LEMS with SCLC patients with complete remission of their tumor still showed improvement in neurological symptoms 52 and 168 months after treatment, respectively. All LEMS patients without SCLC showed a favorable response to treatment and good functional prognosis (modified Rankin Scale 1 or 2) during the follow-up period (48–120 months). Conclusions: In Japanese LEMS patients, the long-term neurological outcome is generally favorable. Our results also suggest that even in LEMS with SCLC patients, successful treatment for their cancer could result in sustained improvement in neurological symptoms.
  • Tomoki Suichi, Sonoko Misawa, Kengo Nagashima, Yasunori Sato, Yuta Iwai, Kanako Katayama, Yukari Sekiguchi, Kazumoto Shibuya, Hiroshi Amino, Yo-Ichi Suzuki, Atsuko Tsuneyama, Keigo Nakamura, Satoshi Kuwabara
    Internal medicine (Tokyo, Japan) 59(9) 1149-1153 2020年5月1日  査読有り
    Objective A randomized controlled trial has shown the efficacy of thalidomide against polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; however, there are still refractory patients. We studied the effects of lenalidomide, a derivative of thalidomide, on patients refractory to thalidomide. Methods This prospective single-arm trial evaluated the safety and efficacy of lenalidomide plus dexamethasone in refractory or recurrent patients with POEMS syndrome. The regimen was administered as six 28-day cycles with lenalidomide on days 1-21 (15 mg in cycle 1, and 25 mg in cycle 2-6) plus dexamethasone once a week (20 mg). The primary endpoints were the rate of reduction in the serum vascular endothelial growth factor (VEGF) level at 24 weeks and the incidence of adverse events. This trial was registered with ClinicalTrial.gov, NCT02193698. Results Between July 2014 and December 2015, five men were enrolled. All patients had been refractory to thalidomide plus dexamethasone for more than 24 weeks. The mean rate of reduction in the serum VEGF level at 24 weeks was 59.6%±8.3% (p=0.0003). The mean serum VEGF level decreased from 2,466±771 pg/mL to 974±340 pg/mL. No serious adverse events were observed, and all patients completed six cycles treatment. Discussion Lenalidomide is a therapeutic option for thalidomide-refractory patients with POEMS syndrome.
  • Kazumoto Shibuya, Atsuko Tsuneyama, Sonoko Misawa, Yukari Sekiguchi, Minako Beppu, Tomoki Suichi, Yo-Ichi Suzuki, Keigo Nakamura, Hiroki Kano, Satoshi Kuwabara
    Journal of neuroimmunology 341 577170-577170 2020年4月15日  査読有り
    In demyelinating polyneuropathies, distribution patterns of demyelination reflect underlying pathogenesis. Median and ulnar nerve conduction studies were reviewed in 85 typical chronic inflammatory demyelinating polyneuropathy (CIDP) patients and 29 multifocal acquired demyelinating sensory and motor neuropathy (MADSAM). Distal latencies were prolonged in typical CIDP and near normal in MADSAM. Abnormal amplitude reductions in the nerve trunks were more frequent in MADSAM than typical CIDP. Presumably because the blood-nerve barrier is anatomically deficient at the distal nerve terminals, antibody-mediated demyelination is a major pathophysiology in typical CIDP. In contrast, blood-nerve barrier breakdown is likely to be predominant in MADSAM.
  • A. G. Kristensen, K. Shibuya, H. Amino, S. Misawa, Y. Sekiguchi, Y. Suzuki, T. Suichi, A. Tsuneyama, K. Nakamura, S. Kuwabara
    Neurophysiology 52(2) 134-139 2020年3月1日  
    Excitability properties at the motor point of the abductor digiti minimi (ADM) muscle were measured using an accelerometer placed on the little finger tip in 31 healthy subjects, and the results were compared with those at the wrist level of the ulnar nerve. ADM motor point stimulation allowed us to demonstrate a significantly shorter strength-duration time constant and smaller threshold changes in deporalizing and hyperpolarizing threshold electrotonus than those at wrist stimulation. At the wrist, hyperpolarizing threshold electrotonus correlated with age (smaller threshold changes), while other excitability indices did not show age-dependent changes at both sites. There were no significant gender differences at these sites. The differences between the wrist and ADM motor point suggest that there are smaller persistent sodium currents and greater inward and outward rectification at the ADM point compared with the wrist. Motor point excitability testing can provide new insights into the pathophysiology of distal motor axons in various peripheral neuropathies and motor disorders.
  • Naoki Hayashi, Naoki Atsuta, Daichi Yokoi, Ryoichi Nakamura, Masahiro Nakatochi, Masahisa Katsuno, Yuishin Izumi, Kazuaki Kanai, Nobutaka Hattori, Akira Taniguchi, Mitsuya Morita, Osamu Kano, Kazumoto Shibuya, Satoshi Kuwabara, Naoki Suzuki, Masashi Aoki, Ikuko Aiba, Kouichi Mizoguchi, Masaya Oda, Ryuji Kaji, Gen Sobue
    Journal of neurology, neurosurgery, and psychiatry 91(3) 285-290 2020年3月  査読有り
    OBJECTIVE: The aim of this study is to describe and clarify the factors affecting the prognosis of Japanese patients with amyotrophic lateral sclerosis (ALS) undergoing tracheostomy invasive ventilation (TIV) therapy. METHODS: We conducted a prospective longitudinal observational case-control study using a multicentre registry. ALS patients who started TIV therapy after registration (TIV group) and those who did not receive TIV (non-TIV group) were included. We compared the survival time between the TIV group and the non-TIV group using a propensity score matching analysis and evaluated the prognostic factors in the TIV group. RESULTS: From February 2006 to January 2018, 190 patients in the TIV group and 1093 patients in the non-TIV group were included in this study. The mean age of disease onset and usage rate of gastrostomy and non-invasive ventilation therapy differed between the groups. In the propensity score matching analysis using known prognostic factors, the median overall survival time of the TIV group was significantly greater than that of the non-TIV group (11.33 years vs 4.61 years; p<0.001). Analysis using the Cox proportional hazard model suggested that older age of onset and respiratory onset was an independent factor for poor prognosis after starting TIV therapy. CONCLUSION: We showed that there was a significant difference of approximately 7 years in life expectancy between Japanese ALS patients who did and did not receive TIV therapy.
  • Keigo Nakamura, Atsuhiko Sugiyama, Kazumoto Shibuya, Satoshi Kuwabara
    Internal medicine (Tokyo, Japan) 59(4) 589-590 2020年2月15日  査読有り
  • Hiroshi Amino, Kazumoto Shibuya, Sonoko Misawa, Yukari Sekiguchi, Minako Beppu, Tomoki Suichi, Yo-Ichi Suzuki, Atsuko Tsuneyama, Satoshi Kuwabara
    Muscle & nerve 61(2) 238-242 2020年2月  査読有り
    INTRODUCTION: Distal nerve terminals, where the blood-nerve barrier is anatomically deficient, are preferentially affected in immune-mediated neuropathies. Excitability alterations near the motor nerve terminals may be more prominent than the nerve trunk in typical chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: In 20 patients with typical CIDP, motor nerve excitability testing was performed at the motor point and wrist of the ulnar nerve, and results were compared with those in 20 healthy persons. RESULTS: Chronic inflammatory demyelinating polyneuropathy patients showed greater threshold changes in hyperpolarizing threshold electrotonus at the motor point (P < .05) but not at the wrist. Strength-duration time constant did not show significant differences between CIDP and controls at both sites. DISCUSSION: Axonal property changes in CIDP are more prominent in distal portions of axons compared with the nerve trunk, presumably due to salient demyelination near the distal nerve terminals. Motor point excitability measurements could elucidate underlying pathophysiology in immune-mediated neuropathies.
  • 叶内 匡, 飯田 真太朗, 澁谷 和幹, 能登 祐一, 木村 英紀, 清水 俊夫, 水野 敏樹, 桑原 聡, 横田 隆徳
    臨床神経学 59(Suppl.) S333-S333 2019年11月  
  • 清水 啓介, 平野 成樹, 柏戸 孝一, 島田 斉, 小島 一歩, 石川 愛, 仲野 義和, 櫻井 透, 鈴木 政秀, 村山 紀子, 石川 萌乃, 焼山 正嗣, 澁谷 和幹, 伊豫 雅臣, 桑原 聡
    臨床神経学 59(Suppl.) S448-S448 2019年11月  
  • 池田 忍, 澁谷 和幹, 鈴木 陽一, 長瀬 さつき, 三澤 園子, 関口 縁, 別府 美奈子, 網野 寛, 水地 智基, 常山 篤子, 荒瀬 彩夏, 鎌田 知子, 山本 修一, 川崎 健治, 松下 一之, 桑原 聡
    臨床神経学 59(Suppl.) S438-S438 2019年11月  
  • 荒瀬 彩夏, 関口 縁, 池田 忍, 三澤 園子, 澁谷 和幹, 別府 美奈子, 長瀬 さつき, 網野 寛, 水地 智基, 鈴木 陽一, 常山 篤子, 鎌田 知子, 山本 修一, 川崎 健治, 松下 一之, 桑原 聡
    臨床神経学 59(Suppl.) S457-S457 2019年11月  
  • 澁谷 和幹
    BRAIN and NERVE 71(11) 1145-1151 2019年11月  
  • 金丸 ゆり, 織田 史子, 澁谷 和幹, 西野 一三, 桑原 聡
    臨床神経学 59(Suppl.) S463-S463 2019年11月  査読有り
  • Kazumoto Shibuya, Toshiki Yoshida, Sonoko Misawa, Yukari Sekiguchi, Minako Beppu, Hiroshi Amino, Yo-Ichi Suzuki, Tomoki Suichi, Atsuko Tsuneyama, Keigo Nakamura, Satoshi Kuwabara
    Internal medicine (Tokyo, Japan) 58(21) 3157-3161 2019年11月1日  査読有り
    Peripheral nerve imaging techniques have recently increasingly revealed their usefulness. We herein describe a man who had a subacute progression of symptom, diffuse and prominent proximal demyelination and conduction block, suggesting a diagnosis of inflammatory demyelinating polyneuropathy. Additional nerve imaging techniques revealed homogeneous and prominent nerve hypertrophy without proximal accentuation and the findings implied inherited polyneuropathies. Intravenous immunoglobulin was administered, and both the symptoms of weakness and findings of nerve conduction studies (NCS) improved. Subsequent genetic testing unveiled Charcot-Marie-Tooth 1A. To diagnose peripheral nerve disorders, a careful history, physical examination and NCS are essential diagnostic tools, but the findings of this case suggest the importance of nerve imaging techniques in clinical situations.
  • 櫻井 透, 平野 成樹, 阿部 翠, 宇治 百合子, 鈴木 弘子, 楠本 千尋, 清水 啓介, 焼山 正嗣, 仲野 義和, 鈴木 政秀, 澁谷 和幹, 村田 淳, 桑原 聡
    Dementia Japan 33(4) 528-528 2019年10月  
  • 夏井 洋和, 叶内 匡, 飯田 真太郎, 赤座 実穂, 澁谷 和幹, 能登 祐一, 木村 英紀, 清水 俊夫, 水野 敏樹, 桑原 聡, 横田 隆徳
    臨床神経生理学 47(5) 505-505 2019年10月  
  • 大森 茂樹, 磯瀬 沙希里, 関口 縁, 別府 美奈子, 網野 寛, 澁谷 和幹, 水地 智基, 鈴木 陽一, 常山 篤子, 三澤 園子, 桑原 聡
    臨床神経生理学 47(5) 445-445 2019年10月  
  • Tomoki Suichi, Sonoko Misawa, Minako Beppu, Sho Takahashi, Yukari Sekiguchi, Kazumoto Shibuya, Hiroshi Amino, Atsuko Tsuneyama, Yo-Ichi Suzuki, Keigo Nakamura, Yasunori Sato, Satoshi Kuwabara
    Neurology 93(10) e975-e983-e983 2019年9月3日  査読有り
    OBJECTIVE: To elucidate current epidemiological, clinical profiles, and treatment of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome. METHODS: We conducted a nationwide survey in 2015 using an established epidemiologic method. Data processing sheets were sent to all neurology and hematology specialist departments throughout Japan to identify patients with POEMS who were seen between April 2012 and March 2015. RESULTS: The estimated number of patients with POEMS was 392 (95% confidence interval [CI] 320-464), and the prevalence was 0.3 per 100,000. Detailed clinical profiles were available for 167 patients. Median age at onset was 54 years (range, 21-84 years), and the ratio of male to female was 1.5. All patients showed polyneuropathy; 89% had monoclonal plasma cell proliferation; and 84% had elevated vascular endothelial growth factor level in whom pretreatment serum or plasma was available (n = 87). Other common features were skin changes (84%), edema/effusion (81%), and organomegaly (76%). A total of 160 patients were treated with any of the following: radiation, corticosteroids, melphalan, thalidomide, lenalidomide, bortezomib, or autologous stem cell transplantation. Primary therapeutic options were thalidomide (n = 86) and autologous stem cell transplantation (n = 71). Thirty-nine patients (24%) were initially treated with corticosteroid alone. The 10-year overall survival was 93% (95% CI 86%-96%). DISCUSSION: This study showed current epidemiologic and clinical status of POEMS syndrome in Japan. A quarter of patients were still inadequately treated with corticosteroid alone, whereas either autologous stem cell transplantation or immunomodulatory drugs improved the prognosis.
  • 澁谷 和幹, 三澤 園子, 関口 縁, 鈴木 陽一, 水地 智基, 常山 篤子, 狩野 裕樹, 小島 雄太, 桑原 聡
    神経免疫学 24(1) 157-157 2019年9月  
  • Keigo Nakamura, Kazumoto Shibuya, Ichizo Nishino, Satoshi Kuwabara
    Internal medicine (Tokyo, Japan) 58(13) 1967-1968 2019年7月1日  査読有り
  • Kazumoto Shibuya, Atsuko Tsuneyama, Minako Beppu, Sonoko Misawa, Yukari Sekiguchi, Hiroshi Amino, Yo-Ichi Suzuki, Tomoki Suichi, Keigo Nakamura, Satoshi Kuwabara
    Muscle & nerve 59(4) E28-E30-E30 2019年4月  査読有り
  • 櫻井 透, 平野 成樹, 阿部 翠, 宇治 百合子, 鈴木 弘子, 楠本 千尋, 清水 啓介, 仲野 義和, 鈴木 政秀, 澁谷 和幹, 村田 淳, 桑原 聡
    高次脳機能研究 39(1) 113-113 2019年3月  
  • Kazumoto Shibuya
    Brain and nerve = Shinkei kenkyu no shinpo 71(3) 257-263 2019年3月  査読有り
    When examining a patient with upper limb atrophy, amyotrophic lateral sclerosis (ALS) should be considered an important disease, because ALS is a devastating disease, and entirely different from cervical spondylotic amyotrophy. The split hand symptom is a very important indicator for diagnosis, because this symptom has been recognized as being specific to ALS. In the split hand symptom, the thenar and first dorsal interosseous (FDI) muscles are preferentially affected. In contrast, the hypothenar muscle (abductor digiti minimi, ADM) is relatively preserved. FDI and ADM muscles are innervated by the same C8/Th1 spinal segments and the same ulnar nerve; however, in this symptom, these muscles are affected differentially, indicating a potentially specific pathological mechanism. In this article, an ALS patient with split hand has been presented. In addition, recent advances in ALS research, the utility of the split hand symptom for diagnosing ALS, and the pathological mechanism of the split hand symptom, have been introduced.
  • Geevasinga N, Howells J, Menon P, van den Bos M, Shibuya K, Matamala JM, Park SB, Byth K, Kiernan MC, Vucic S
    Neurology 92(6) e536-e547 2019年2月5日  査読有り
  • Kazumoto Shibuya, Sonoko Misawa, Yukari Sekiguchi, Minako Beppu, Hiroshi Amino, Tomoki Suichi, Yo-Ichi Suzuki, Atsuko Tsuneyama, Satoshi Kuwabara
    Journal of neurology, neurosurgery, and psychiatry 90(2) 242-243 2019年2月  査読有り
  • Tomoki Suichi, Sonoko Misawa, Yasunori Sato, Minako Beppu, Emiko Sakaida, Yukari Sekiguchi, Kazumoto Shibuya, Keisuke Watanabe, Hiroshi Amino, Satoshi Kuwabara
    Journal of neurology, neurosurgery, and psychiatry 90(2) 133-137 2019年2月  査読有り
    OBJECTIVE: To propose the optimal diagnostic criteria for polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome using appropriate statistical methods and disease controls. METHODS: This retrospective cohort study included 104 consecutive patients with suspected POEMS syndrome, among whom a gold standard group of 60 patients with definitive POEMS syndrome diagnosis were followed for at least 12 months to strictly exclude other disorders mimicking POEMS syndrome and to confirm response to POEMS syndrome-specific treatment. Thirty patients with chronic inflammatory demyelinating polyradiculoneuropathy (demyelinating polyradiculoneuropathy controls) and 30 with multiple myeloma or immunoglobulin light chain amyloidosis (monoclonal plasma cell proliferation controls) were also included. Logistic regression analyses were performed to determine optimal combination of clinical and laboratory abnormalities, characteristic of POEMS syndrome. RESULTS: The diagnostic criteria were statistically defined as the presence of the three major criteria (polyneuropathy (typically demyelinating), monoclonal plasma cell proliferative disorder and elevated vascular endothelial growth factor) and at least two of the four minor criteria (oedema/effusion, skin changes, organomegaly and sclerotic bone lesions), based on best performance by area under the receiver operating characteristic curve analyses. The sensitivity and specificity were 100% and 100%, respectively; the diagnostic accuracy of the proposed criteria was equivalent to somewhat complicated previous criteria. CONCLUSIONS: The statistically defined, simple diagnostic criteria for POEMS syndrome could accelerate early diagnosis and treatment, thereby contribute to better outcome in patients with this serious disease. Prospective larger studies are required to confirm the validity.
  • 金井 数明, 横田 隆徳, 澁谷 和幹, 叶内 匡, 中里 朋子, 岩井 雄太, 三澤 園子, 大山 彦光, 下 泰司, 清水 俊夫, 服部 信孝, 桑原 聡
    臨床神経学 58(Suppl.) S230-S230 2018年12月  査読有り
  • Sugimoto K, Hiwasa T, Shibuya K, Hirano S, Beppu M, Isose S, Arai K, Takiguchi M, Kuwabara S, Mori M
    Journal of neuroimmunology 325 54-60 2018年12月  査読有り
  • Tsuneyama Atsuko, Shibuya Kazumoto, Misawa Sonoko, Sekiguchi Yukari, Amino Hiroshi, Suichi Tomoki, Suzuki Youichi, Kuwabara Satoshi
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 23(4) 294-294 2018年12月  査読有り
  • Amino Hiroshi, Shibuya Kazumoto, Misawa Sonoko, Sekiguchi Yukari, Suichi Tomoki, Suzuki Youichi, Tsuneyama Atsuko, Kuwabara Satoshi
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 23(4) 381-381 2018年12月  査読有り
  • Suichi Tomoki, Misawa Sonoko, Sekiguchi Yukari, Shibuya Kazumoto, Amino Hiroshi, Tsuneyama Atsuko, Suzuki Youichi, Kuwabara Satoshi
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 23(4) 292-292 2018年12月  査読有り

MISC

 387

共同研究・競争的資金等の研究課題

 9